Calcimedica presents data from preclinical studies of auxora in acute kidney injury at the 29th international aki & crrt conference

Therapeutic treatment with auxora shown to hasten the recovery of kidney function and improve survival in a rat model of acute kidney injury (aki) preclinical results are consistent with clinical observations made with auxora, supporting the kourage trial in patients with severe aki that will start enrolling in 2q 2024 la jolla, calif. , march 13, 2024 /prnewswire/ -- calcimedica inc. (calcimedica or the company) (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, last evening presented data from preclinical studies of auxora™ in acute kidney injury (aki) at the 29th international acute kidney injury and continuous renal replacement therapy conference (aki & crrt) in san diego, ca.
CALC Ratings Summary
CALC Quant Ranking